- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
AGEN Market Currents
more »
-
October 18, 2011 Agenus (AGEN +50%) skyrockets after the company reports a Phase 3 trial of GlaxoSmithKline's (GSK) malaria vaccine, which contains an Agenus drug agent, found the vaccine delivered positive results. Agenus is entitled to milestone payments for the vaccine, as well as "royalties for 10 years after commercial launch."
1 Comment[Healthcare, On the Move]
AGEN in Focus
more »
AGEN Related Articles
more »
AGEN News
more »
-
at MarketWatch.com (Jul 27, 2010)
-
at MarketWatch.com (May 20, 2010)
AGEN Press Releases and Filings
more »
-
GlobeNewswire (Apr 25, 2012)
-
GlobeNewswire (Apr 17, 2012)
-
GlobeNewswire (Mar 20, 2012)
-
GlobeNewswire (Jan 4, 2012)
-
Marketwire (Dec 20, 2011)
AGEN Latest Transcript
more »
-
Mon, Mar 5
AGEN Cramer
more »
Currently, there are no Cramer articles on AGEN.
AGEN Instablog posts
more »
AGEN vs. ETF Alternatives
Company Description
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates... More
